United States Cancer Diagnostics Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2034

Market Growth Rate: 8.3% (2025-2033)

Market Size in 2024: USD 53 Billion

Market Forecast in 2033: USD 108.2 Billion

The United States cancer diagnostics market is on a trajectory of remarkable growth, propelled by advancements in medical technology and evolving healthcare priorities. According to the latest report by IMARC Group, the market size was valued at USD 53 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 108.2 Billion by 2033, exhibiting a CAGR of 8.3% from 2025-2033.

The increasing prevalence of cancer has driven the need for early detection solutions that offer accuracy, reliability, and faster results. One of the key factors shaping the market is the adoption of personalized diagnostic techniques. These innovative approaches not only improve the detection process but also pave the way for customized treatment plans, leading to better patient outcomes. Furthermore, the integration of cutting-edge technologies such as artificial intelligence (AI) and next-generation sequencing (NGS) into cancer diagnostics has revolutionized the way healthcare providers identify and manage cancer cases.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/united-states-cancer-diagnostics-market/requestsample

United States Cancer Diagnostics Industry Trends and Drivers:

The demand for precision in identifying genetic mutations associated with various cancers is driving investments in research and development. This surge in innovation has given rise to sophisticated diagnostic tools and techniques, including liquid biopsy and molecular diagnostics, which are gaining widespread adoption across healthcare facilities. These advancements are enabling healthcare professionals to detect cancer at an earlier stage, which is critical for effective treatment and improved survival rates. Additionally, the increasing awareness about the importance of early cancer screening is encouraging individuals to seek diagnostic services, further fueling market growth. Public health campaigns and initiatives by government organizations and non-profits play a significant role in educating the population and boosting the adoption of diagnostic tools.

In the coming years, the cancer diagnostics market in the United States is expected to continue its upward momentum, supported by robust technological progress and a growing emphasis on patient-centric care. The healthcare sector is witnessing a shift towards value-based care models, which prioritize quality and outcomes over volume. This transition is fostering collaboration among stakeholders, including diagnostic equipment manufacturers, healthcare providers, and researchers. Key trends include the development of non-invasive diagnostic techniques, integration of digital platforms for remote monitoring, and the expansion of specialized diagnostic labs. These advancements, combined with a supportive regulatory environment and increasing investments in healthcare infrastructure, are positioning the United States as a leader in cancer diagnostics.

United States Cancer Diagnostics Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest United States cancer diagnostics market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.

The report has segmented the market into the following categories:

Product Insights:

• Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
  • Others
• Instruments
  • Pathology-Based Instruments
  • Imaging Instruments
  • Biopsy Instruments

Technology Insights:

• IVD Testing
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Others
• Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound
• Biopsy Technique

Application Insights:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Others

End User Insights:

• Hospitals and Clinics
• Diagnostic Laboratories
• Others

Regional Insights:

• Northeast
• Midwest
• South
• West

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=20391&flag=C

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145